146 related articles for article (PubMed ID: 17196360)
1. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
Samelis GF; Ekmektzoglou KA; Zografos GC
Eur J Surg Oncol; 2007 Oct; 33(8):942-50. PubMed ID: 17196360
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors.
von Mehren M; Watson JC
Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
[TBL] [Abstract][Full Text] [Related]
5. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Renouf DJ; Wilson L; Blanke CD
Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
[TBL] [Abstract][Full Text] [Related]
6. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumor: 5 years later.
van der Zwan SM; DeMatteo RP
Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
9. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Heinrich MC; Corless CL
J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
Papaetis GS; Syrigos KN
Cancer Metastasis Rev; 2010 Mar; 29(1):151-70. PubMed ID: 20112054
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Cassier PA; Dufresne A; Arifi S; El Sayadi H; Labidi I; Ray-Coquard I; Tabone S; Méeus P; Ranchère D; Sunyach MP; Decouvelaere AV; Alberti L; Blay JY
Expert Opin Pharmacother; 2008 May; 9(7):1211-22. PubMed ID: 18422477
[TBL] [Abstract][Full Text] [Related]
12. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
13. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
[TBL] [Abstract][Full Text] [Related]
14. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
15. [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
Sakakura C; Miyagawa K; Fukuda K; Kin S; Nakase Y; Kuriu Y; Nakashima S; Yoshikawa T; Yamaoka N; Sagara Y; Hagiwara A; Yamagishi H
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1739-41. PubMed ID: 16315926
[TBL] [Abstract][Full Text] [Related]
16. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
17. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
Neuhaus SJ; Clark MA; Hayes AJ; Thomas JM; Judson I
ANZ J Surg; 2005 Mar; 75(3):165-72. PubMed ID: 15777399
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate: A designer drug.
Panigrahi I; Naithani R
J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
[TBL] [Abstract][Full Text] [Related]
20. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]